Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings

Monica Loi, Daniela Di Paolo, Marco Soster, Chiara Brignole, Alice Bartolini, Laura Emionite, Jessica Sun, Pamela Becherini, Flavio Curnis, Andrea Petretto, Monica Sani, Alessandro Gori, Marco Milanese, Claudio Gambini, Renato Longhi, Michele Cilli, Theresa M. Allen, Federico Bussolino, Wadih Arap, Renata PasqualiniAngelo Corti, Mirco Ponzoni, Serena Marchiò, Fabio Pastorino

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Molecular targeting of drug delivery nanocarriers is expected to improve their therapeutic index while decreasing their toxicity. Here we report the identification and characterization of novel peptide ligands specific for cells present in high-risk neuroblastoma (NB), a childhood tumor mostly refractory to current therapies. To isolate such targeting moieties, we performed combined in vitro/ex-vivo phage display screenings on NB cell lines and on tumors derived from orthotopic mouse models of human NB. By designing proper subtractive protocols, we identified phage clones specific either for the primary tumor, its metastases, or for their respective stromal components. Globally, we isolated 121 phage-displayed NB-binding peptides: 26 bound the primary tumor, 15 the metastatic mass, 57 and 23 their respective microenvironments. Of these, five phage clones were further validated for their specific binding ex-vivo to biopsies from stage IV NB patients and to NB tumors derived from mice. All five clones also targeted tumor cells and vasculature in vivo when injected into NB-bearing mice. Coupling of the corresponding targeting peptides with doxorubicin-loaded liposomes led to a significant inhibition in tumor volume and enhanced survival in preclinical NB models, thereby paving the way to their clinical development.

Original languageEnglish
Pages (from-to)233-241
Number of pages9
JournalJournal of Controlled Release
Volume170
Issue number2
DOIs
Publication statusPublished - 2013

Fingerprint

Neuroblastoma
Bacteriophages
Peptides
Pharmaceutical Preparations
Clone Cells
Neoplasms
Drug Delivery Systems
Tumor Burden
Tumor Cell Line
Liposomes
Doxorubicin
Neoplasm Metastasis
Ligands
Biopsy
Survival
Therapeutics

Keywords

  • Liposomes
  • Nanocarriers
  • Neuroblastoma
  • Peptides
  • Phage display screening
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Medicine(all)

Cite this

Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. / Loi, Monica; Di Paolo, Daniela; Soster, Marco; Brignole, Chiara; Bartolini, Alice; Emionite, Laura; Sun, Jessica; Becherini, Pamela; Curnis, Flavio; Petretto, Andrea; Sani, Monica; Gori, Alessandro; Milanese, Marco; Gambini, Claudio; Longhi, Renato; Cilli, Michele; Allen, Theresa M.; Bussolino, Federico; Arap, Wadih; Pasqualini, Renata; Corti, Angelo; Ponzoni, Mirco; Marchiò, Serena; Pastorino, Fabio.

In: Journal of Controlled Release, Vol. 170, No. 2, 2013, p. 233-241.

Research output: Contribution to journalArticle

Loi, Monica ; Di Paolo, Daniela ; Soster, Marco ; Brignole, Chiara ; Bartolini, Alice ; Emionite, Laura ; Sun, Jessica ; Becherini, Pamela ; Curnis, Flavio ; Petretto, Andrea ; Sani, Monica ; Gori, Alessandro ; Milanese, Marco ; Gambini, Claudio ; Longhi, Renato ; Cilli, Michele ; Allen, Theresa M. ; Bussolino, Federico ; Arap, Wadih ; Pasqualini, Renata ; Corti, Angelo ; Ponzoni, Mirco ; Marchiò, Serena ; Pastorino, Fabio. / Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. In: Journal of Controlled Release. 2013 ; Vol. 170, No. 2. pp. 233-241.
@article{2cd47e3bd2204b598299cb7bd3763fb2,
title = "Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings",
abstract = "Molecular targeting of drug delivery nanocarriers is expected to improve their therapeutic index while decreasing their toxicity. Here we report the identification and characterization of novel peptide ligands specific for cells present in high-risk neuroblastoma (NB), a childhood tumor mostly refractory to current therapies. To isolate such targeting moieties, we performed combined in vitro/ex-vivo phage display screenings on NB cell lines and on tumors derived from orthotopic mouse models of human NB. By designing proper subtractive protocols, we identified phage clones specific either for the primary tumor, its metastases, or for their respective stromal components. Globally, we isolated 121 phage-displayed NB-binding peptides: 26 bound the primary tumor, 15 the metastatic mass, 57 and 23 their respective microenvironments. Of these, five phage clones were further validated for their specific binding ex-vivo to biopsies from stage IV NB patients and to NB tumors derived from mice. All five clones also targeted tumor cells and vasculature in vivo when injected into NB-bearing mice. Coupling of the corresponding targeting peptides with doxorubicin-loaded liposomes led to a significant inhibition in tumor volume and enhanced survival in preclinical NB models, thereby paving the way to their clinical development.",
keywords = "Liposomes, Nanocarriers, Neuroblastoma, Peptides, Phage display screening, Targeted therapy",
author = "Monica Loi and {Di Paolo}, Daniela and Marco Soster and Chiara Brignole and Alice Bartolini and Laura Emionite and Jessica Sun and Pamela Becherini and Flavio Curnis and Andrea Petretto and Monica Sani and Alessandro Gori and Marco Milanese and Claudio Gambini and Renato Longhi and Michele Cilli and Allen, {Theresa M.} and Federico Bussolino and Wadih Arap and Renata Pasqualini and Angelo Corti and Mirco Ponzoni and Serena Marchi{\`o} and Fabio Pastorino",
year = "2013",
doi = "10.1016/j.jconrel.2013.04.029",
language = "English",
volume = "170",
pages = "233--241",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings

AU - Loi, Monica

AU - Di Paolo, Daniela

AU - Soster, Marco

AU - Brignole, Chiara

AU - Bartolini, Alice

AU - Emionite, Laura

AU - Sun, Jessica

AU - Becherini, Pamela

AU - Curnis, Flavio

AU - Petretto, Andrea

AU - Sani, Monica

AU - Gori, Alessandro

AU - Milanese, Marco

AU - Gambini, Claudio

AU - Longhi, Renato

AU - Cilli, Michele

AU - Allen, Theresa M.

AU - Bussolino, Federico

AU - Arap, Wadih

AU - Pasqualini, Renata

AU - Corti, Angelo

AU - Ponzoni, Mirco

AU - Marchiò, Serena

AU - Pastorino, Fabio

PY - 2013

Y1 - 2013

N2 - Molecular targeting of drug delivery nanocarriers is expected to improve their therapeutic index while decreasing their toxicity. Here we report the identification and characterization of novel peptide ligands specific for cells present in high-risk neuroblastoma (NB), a childhood tumor mostly refractory to current therapies. To isolate such targeting moieties, we performed combined in vitro/ex-vivo phage display screenings on NB cell lines and on tumors derived from orthotopic mouse models of human NB. By designing proper subtractive protocols, we identified phage clones specific either for the primary tumor, its metastases, or for their respective stromal components. Globally, we isolated 121 phage-displayed NB-binding peptides: 26 bound the primary tumor, 15 the metastatic mass, 57 and 23 their respective microenvironments. Of these, five phage clones were further validated for their specific binding ex-vivo to biopsies from stage IV NB patients and to NB tumors derived from mice. All five clones also targeted tumor cells and vasculature in vivo when injected into NB-bearing mice. Coupling of the corresponding targeting peptides with doxorubicin-loaded liposomes led to a significant inhibition in tumor volume and enhanced survival in preclinical NB models, thereby paving the way to their clinical development.

AB - Molecular targeting of drug delivery nanocarriers is expected to improve their therapeutic index while decreasing their toxicity. Here we report the identification and characterization of novel peptide ligands specific for cells present in high-risk neuroblastoma (NB), a childhood tumor mostly refractory to current therapies. To isolate such targeting moieties, we performed combined in vitro/ex-vivo phage display screenings on NB cell lines and on tumors derived from orthotopic mouse models of human NB. By designing proper subtractive protocols, we identified phage clones specific either for the primary tumor, its metastases, or for their respective stromal components. Globally, we isolated 121 phage-displayed NB-binding peptides: 26 bound the primary tumor, 15 the metastatic mass, 57 and 23 their respective microenvironments. Of these, five phage clones were further validated for their specific binding ex-vivo to biopsies from stage IV NB patients and to NB tumors derived from mice. All five clones also targeted tumor cells and vasculature in vivo when injected into NB-bearing mice. Coupling of the corresponding targeting peptides with doxorubicin-loaded liposomes led to a significant inhibition in tumor volume and enhanced survival in preclinical NB models, thereby paving the way to their clinical development.

KW - Liposomes

KW - Nanocarriers

KW - Neuroblastoma

KW - Peptides

KW - Phage display screening

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84879491627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879491627&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2013.04.029

DO - 10.1016/j.jconrel.2013.04.029

M3 - Article

C2 - 23714122

AN - SCOPUS:84879491627

VL - 170

SP - 233

EP - 241

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -